Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Hepatocellular 2Solid Cancers 1Liver Cirrhosis 1Hepatitis D 1Hepatitis B 1Fibrosis 1Esophageal and Gastric Varices 1Carcinoma, Renal Cell 1

Interventions

Bevacizumab 7Paclitaxel 3vesencumab 2atezolizumab 2Carboplatin 21-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one 2pertuzumab 1peginterferon alfa-2a 1parsatuzumab 1ovcon 35 1onartuzumab 1obinutuzumab 1ipatasertib 1emactuzumab 1Trastuzumab 1Rosiglitazone 1Pemetrexed 1Ipilimumab 1Interferon alpha-2 1HhAntag691 1GDC-0623 1GDC-0152 1Docetaxel 1Cisplatin 1Capecitabine 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Cancers × peginterferon alfa-2a × Clear all
NCT02174172 2020-05-12

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
158 enrolled

Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡